论文部分内容阅读
目的:观察补肾中药复方首参颗粒对颈动脉粥样硬化(atherosclerosis,AS)患者外周血端粒、端粒酶的影响,初步探讨其作用机制。方法:选取156例颈动脉粥样硬化患者,随机分为治疗组83例和对照组73例,对照组口服普伐他汀,治疗组服用首参颗粒,疗程均为6个月。于治疗前后分别采用实时荧光定量PCR(Real-Time Quantitative Polymerase Chain Reaction,RQ PCR)方法检测外周血端粒、端粒酶的变化。结果:中药组治疗6月后端粒长度同治疗前比较均有显著性差异(P<0.01),西药组治疗6月后端粒长度同治疗前比较有显著性差异(P<0.05),中药组和西药组比较无统计学差异(P>0.05)。两组治疗6个月后端粒酶活性均较治疗前提高(P<0.05),中药组和西药组比较无统计学差异(P>0.05)。结论:调控颈动脉粥样硬化患者外周血端粒长度及端粒酶活性可能是补肾中药复方首参颗粒有效作用机制之一。
Objective: To observe the effect of Bushen Chinese medicine compound ginseng granules on telomerase and telomerase in peripheral blood of patients with carotid atherosclerosis (AS) and to explore its mechanism. Methods: A total of 156 patients with carotid atherosclerosis were randomly divided into treatment group (n = 83) and control group (n = 73). Pravastatin was given to the control group. The treatment group took the first ginseng granules for 6 months. Real-time Quantitative Polymerase Chain Reaction (RQ PCR) method was used to detect the changes of telomere and telomerase in peripheral blood before and after treatment. Results: The telomere length of the Chinese medicine group after 6 months of treatment was significantly different from that before treatment (P <0.01). The telomere length of the western medicine group after 6 months of treatment was significantly lower than that before treatment (P <0.05) There was no significant difference between the two groups (P> 0.05). The telomerase activity in both groups after treatment for 6 months was higher than that before treatment (P <0.05). There was no significant difference between the two groups (P> 0.05). CONCLUSION: The regulation of telomere length and telomerase activity in peripheral blood of patients with carotid atherosclerosis may be one of the effective mechanisms of Bushen Chinese medicine compound ginseng granules.